JP2008511608A5 - - Google Patents

Download PDF

Info

Publication number
JP2008511608A5
JP2008511608A5 JP2007529033A JP2007529033A JP2008511608A5 JP 2008511608 A5 JP2008511608 A5 JP 2008511608A5 JP 2007529033 A JP2007529033 A JP 2007529033A JP 2007529033 A JP2007529033 A JP 2007529033A JP 2008511608 A5 JP2008511608 A5 JP 2008511608A5
Authority
JP
Japan
Prior art keywords
composition
omv
concentration
serum
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007529033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008511608A (ja
Filing date
Publication date
Priority claimed from GBGB0419627.5A external-priority patent/GB0419627D0/en
Application filed filed Critical
Publication of JP2008511608A publication Critical patent/JP2008511608A/ja
Publication of JP2008511608A5 publication Critical patent/JP2008511608A5/ja
Pending legal-status Critical Current

Links

JP2007529033A 2004-09-03 2005-09-05 髄膜炎菌外膜ベシクルに関する改良 Pending JP2008511608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419627.5A GB0419627D0 (en) 2004-09-03 2004-09-03 Immunogenic bacterial vesicles with outer membrane proteins
PCT/IB2005/002801 WO2006024946A2 (en) 2004-09-03 2005-09-05 Improvements relating to meningococcal outer membrane vesicles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011185225A Division JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Publications (2)

Publication Number Publication Date
JP2008511608A JP2008511608A (ja) 2008-04-17
JP2008511608A5 true JP2008511608A5 (cg-RX-API-DMAC7.html) 2011-10-13

Family

ID=33156002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007529033A Pending JP2008511608A (ja) 2004-09-03 2005-09-05 髄膜炎菌外膜ベシクルに関する改良
JP2011185225A Pending JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011185225A Pending JP2011236254A (ja) 2004-09-03 2011-08-26 髄膜炎菌外膜ベシクルに関する改良

Country Status (13)

Country Link
US (1) US8808711B2 (cg-RX-API-DMAC7.html)
EP (1) EP1784213B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008511608A (cg-RX-API-DMAC7.html)
CN (2) CN101115501A (cg-RX-API-DMAC7.html)
AU (1) AU2005278896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514883A (cg-RX-API-DMAC7.html)
CA (1) CA2578588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2527859T3 (cg-RX-API-DMAC7.html)
GB (1) GB0419627D0 (cg-RX-API-DMAC7.html)
MX (1) MX2007002633A (cg-RX-API-DMAC7.html)
NZ (1) NZ553521A (cg-RX-API-DMAC7.html)
RU (1) RU2420312C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006024946A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
AU2015289193A1 (en) * 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药(苏州)股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2001510169A (ja) 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
US7031284B2 (en) * 2003-03-03 2006-04-18 Interdigital Technology Corporation Wireless communication method and apparatus for optimizing multi-user detection
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
ES2337309T5 (es) * 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna

Similar Documents

Publication Publication Date Title
RU2007111838A (ru) Усовершенствования, касающиеся везикул внешней мембраны менингококков
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
Wedemeyer et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection
Keiser et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression
ES2251124T3 (es) Vacuna que comprende un antigeno de streptococcus pneumoniae adyuvado por un oligonucleotido cpg.
WO2005105141A3 (en) Combined meningococcal conjugates with common carrier protein
HU228384B1 (en) Vaccine compositions
JP2008526939A5 (cg-RX-API-DMAC7.html)
JP2009525260A5 (cg-RX-API-DMAC7.html)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP5806204B2 (ja) 肺炎球菌血清型14の糖を含む組み合わせ
HU229968B1 (hu) Sztreptokokkusz oltóanyag
JP2007516219A5 (cg-RX-API-DMAC7.html)
JP2007535527A5 (cg-RX-API-DMAC7.html)
JP2004512269A5 (cg-RX-API-DMAC7.html)
JP2021001182A5 (cg-RX-API-DMAC7.html)
RU2006142158A (ru) Вакцинация менингококковыми конъюгатами
JP2015521595A (ja) 血清群x髄膜炎菌のためのワクチン
JP2020525495A (ja) 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
CA2528312A1 (en) Methods of managing the symptoms of premenstrual syndrome
JP2021066727A5 (cg-RX-API-DMAC7.html)
Rosen et al. Chronic meningococcal meningitis: an association with C5 deficiency
Chawla et al. What's new in clinical pharmacology and therapeutics
JP2007197423A (ja) フドステインと抗コリン薬を含有する医薬組成物
US20050234024A1 (en) Materials and methods for the treatment of ulcerative colitis